Tiragolumab Biosimilar – Anti-TIGIT, VSIG9, VSTM3 mAb – Research Grade

Description of Tiragolumab Biosimilar - Anti-TIGIT, VSIG9, VSTM3 mAb - Research Grade

Introduction

Tiragolumab Biosimilar, also known as Anti-TIGIT, VSIG9, VSTM3 mAb (monoclonal antibody), is a novel therapeutic agent that has shown promising results in the treatment of various types of cancers. This biosimilar is a research grade antibody that targets specific immune checkpoint proteins, making it a potential candidate for immunotherapy.

Structure

Tiragolumab Biosimilar is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a structure similar to natural antibodies found in the body. It is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The molecular weight of Tiragolumab Biosimilar is approximately 150 kDa.

Activity

Tiragolumab Biosimilar targets three specific immune checkpoint proteins: TIGIT (T cell immunoglobulin and ITIM domain), VSIG9 (V-set and immunoglobulin domain-containing 9), and VSTM3 (V-set and transmembrane domain-containing 3). These proteins are found on the surface of immune cells and play a crucial role in regulating immune responses.

TIGIT is a co-inhibitory receptor expressed on T cells, natural killer (NK) cells, and regulatory T cells. It interacts with its ligands, CD155 and CD112, on antigen-presenting cells, leading to the suppression of immune responses. VSIG9 and VSTM3 also act as co-inhibitory receptors and are expressed on T cells and NK cells.

By targeting these immune checkpoint proteins, Tiragolumab Biosimilar blocks their interaction with their ligands, thereby preventing the suppression of immune responses. This allows for the activation of immune cells, leading to the destruction of cancer cells.

Application

Tiragolumab Biosimilar has shown promising results in the treatment of various types of cancers, including lung cancer, breast cancer, and melanoma. It is currently being evaluated in clinical trials as a monotherapy and in combination with other cancer treatments.

In a phase I clinical trial, Tiragolumab Biosimilar showed promising results in patients with advanced solid tumors. It was well-tolerated and showed anti-tumor activity in patients with lung cancer, melanoma, and other solid tumors. In a phase II clinical trial, Tiragolumab Biosimilar in combination with another immunotherapy drug, atezolizumab, showed improved outcomes in patients with non-small cell lung cancer.

Tiragolumab Biosimilar is also being studied in combination with chemotherapy, radiation therapy, and other targeted therapies. These trials aim to evaluate the safety and efficacy of Tiragolumab Biosimilar in combination with other treatments and to determine the optimal treatment regimen for different types of cancers.

Conclusion

Tiragolumab Biosimilar is a promising therapeutic agent for the treatment of various types of cancers. Its unique mechanism of action, targeting specific immune checkpoint proteins, makes it a potential candidate for immunotherapy. With ongoing clinical trials, Tiragolumab Biosimilar has shown promising results and has the potential to improve outcomes for cancer patients. Further research and development of this biosimilar may lead to its approval for clinical use and provide a new treatment option for cancer patients.

SDS-PAGE for Tiragolumab Biosimilar - Anti-TIGIT, VSIG9, VSTM3 mAb

Tiragolumab Biosimilar - Anti-TIGIT, VSIG9, VSTM3 mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Immobilized Human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) recombinant protein (cat. No.PX-P4036) at 0.5µg/mL (100µL/well) can bind to Tiragolumab Biosimilar - Anti-TIGIT, VSIG9, VSTM3 mAb (cat. No.PX-TA1487) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450